Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Rhea-AI Summary

Palisade Bio (Nasdaq: PALI) announced on October 9, 2025 that it has cancelled its previously adjourned special meeting of stockholders that had been scheduled to reconvene on October 10, 2025. The meeting was earlier reconvened on September 26, 2025 but adjourned without business due to a lack of quorum.

The company said it still has not received sufficient proxies to constitute a quorum and has withdrawn from stockholder consideration the proposals included in its definitive proxy statement filed with the SEC on August 18, 2025.

Positive

• None.

Negative

• Special meeting scheduled for Oct 10, 2025 cancelled
• Company withdrew proposals filed on Aug 18, 2025 from stockholder consideration
• Meeting reconvened on Sept 26, 2025 adjourned due to lack of quorum

Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Company determined to cancel its previously adjourned special meeting of stockholders (the “Special Meeting”), which had been scheduled to reconvene on Friday, October 10, 2025, at 10:00 a.m. Pacific Time.

The Special Meeting was previously adjourned to, and reconvened on, September 26, 2025, but was adjourned again without any business being conducted, due to the lack of the required quorum as of the meeting time. As of today, the Company has still not received proxies that would constitute a quorum and has decided to cancel the Special Meeting and to withdraw from consideration by the Company’s stockholders the proposals set forth in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 18, 2025.

About Palisade Bio

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com 

FAQ

Why did Palisade Bio (PALI) cancel the special meeting scheduled for October 10, 2025?

The company cancelled the meeting because it has not received sufficient proxies to constitute a quorum as of the reconvened meeting dates.

What proposals were withdrawn by Palisade Bio (PALI) after cancelling the October 2025 special meeting?

Palisade Bio withdrew the proposals that were set forth in the company’s definitive proxy statement filed with the SEC on August 18, 2025.

When was the special meeting of Palisade Bio (PALI) previously reconvened and adjourned?

The meeting was reconvened on September 26, 2025 but was adjourned without any business being conducted due to lack of quorum.

Will Palisade Bio (PALI) reschedule the cancelled special meeting?

The company announced cancellation and withdrawal of the proposals; no rescheduling was announced in the company’s October 9, 2025 notice.

How does the lack of quorum affect Palisade Bio (PALI) stockholders?

Because a quorum was not achieved, the company did not conduct business at the reconvened meeting and withdrew the proposals from stockholder consideration.